The Newest JAK inhibitor for Psoriatic Arthritis: Upadacitinib (Rinvoq)
The disease burden and current treatment landscape
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease with complex clinical manifestations such as plaque psoriasis, dactylitis and enthesitis. Patients with PsA often experience fatigue, physical function limitations, sleep disturbance, as well as diminished work capacity and social participation. The . . .
Login or Sign Up as a healthcare professional to read the full article.